Jump to Header Jump to Main Content Jump to Footer

Ph II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas

Daniela Bota


A Study On:

  • Brain and Nervous System

Status:

  • Open

Eligibility

Adults

Interested in joining this trial?

Official Title

Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas

Details

This phase II trial studies how well vemurafenib and cobimetinib work in treating patients with BRAF V600E mutation positive craniopharyngioma. Vemurafenib and cobimetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth


Eligibility

You can join if...

Inclusion Criteria:

  • Pre-registration: Patients must have local diagnosis of papillary craniopharyngioma and have tissue slides available for submission to central pathology review; central pathology review will include immunohistochemistry (IHC) testing for BRAF V600E mutation (VE1 clone) and beta-catenin IHC (membranous, non-nuclear pattern) if needed to confirm diagnosis of papillary craniopharyngioma
  • Histologically proven papillary craniopharyngioma as documented by central pathology review with positive BRAF V600E mutation by IHC
  • Not pregnant and not nursing; for women of childbearing potential only, a negative pregnancy test done =< 7 days prior to registration is required

Get in touch with our study team